Avapritinib Ayvakit Advanced SM — PatSnap Eureka
Avapritinib (Ayvakit) in Advanced Systemic Mastocytosis: Patent & Literature Intelligence
Avapritinib is a selective KIT D816V inhibitor developed by Blueprint Medicines and now part of the Sanofi portfolio. The PATHFINDER trial and its expansion cohorts are central to establishing avapritinib's clinical profile in this rare and life-threatening mast cell neoplasm. Search the full patent and literature landscape with PatSnap Eureka.
Structured Intelligence Framework for Avapritinib & Advanced SM
The patent and literature landscape for avapritinib spans three independent analytical dimensions, each covering a distinct aspect of the KIT D816V inhibitor's scientific, clinical, and commercial profile.
KIT D816V Inhibition Mechanisms & Avapritinib Pharmacology
This dimension covers the molecular pharmacology of avapritinib as a selective KIT D816V inhibitor, including binding kinetics, selectivity profiles, and resistance mechanisms relevant to advanced systemic mastocytosis. Patent filings in this space document structural chemistry and formulation innovations by life sciences innovators.
KIT D816V · Mast cell pharmacologyPATHFINDER Trial & Systemic Mastocytosis Clinical Applications
The PATHFINDER trial (NCT03580655) and its expansion cohorts have been central to establishing avapritinib's clinical profile in advanced systemic mastocytosis. This dimension captures clinical publications, trial design patents, and outcome data from the PATHFINDER-era 2018–2024 window.
NCT03580655 · PATHFINDER expansionBlueprint Medicines / Sanofi Assignee Landscape & Combination Strategies
Following the Sanofi acquisition, the IP ownership landscape for avapritinib requires analysis of both Blueprint Medicines and Sanofi as assignees. This dimension covers combination therapy strategies, patent landscape analytics, and post-acquisition commercial intelligence relevant to the advanced SM indication.
Blueprint Medicines · Sanofi · Post-acquisition IPGrounded Analysis: Why Source-Verified Data Matters
Generating analysis without grounded patent or literature records risks fabricating patent numbers, assignee attributions, or misrepresenting clinical trial status and regulatory decisions. All intelligence on this topic must be traceable to verifiable sources including EPO, PatSnap, and ClinicalTrials.gov records.
Verifiable sources · No fabricationRecommended Search Strategy for Avapritinib Intelligence
When primary queries return null results, broadening to proximal terms and applying date-range filters surfaces PATHFINDER-era publications and patent filings. The strategies below are drawn directly from the recommended next steps in the source analysis.
Alternative Query Terms for Avapritinib Patent Discovery
Four recommended search terms to capture proximal literature when primary avapritinib queries return no results, per the source analysis.
Recommended Date Range Filter: 2018–2024 PATHFINDER Era
Applying a 2018–2024 window aligns searches with PATHFINDER-era publications and patent filings for avapritinib in advanced systemic mastocytosis.
KIT D816V Inhibition and the PATHFINDER Trial Framework
Avapritinib (Ayvakit) is a selective KIT D816V inhibitor developed by Blueprint Medicines for advanced systemic mastocytosis — a rare and life-threatening mast cell neoplasm. The KIT D816V mutation drives aberrant mast cell proliferation, making it the primary therapeutic target in this indication.
The PATHFINDER trial (NCT03580655) and its expansion cohorts have been central to establishing avapritinib's clinical profile. The trial spans KIT D816V inhibition mechanisms, systemic mastocytosis clinical applications, and the post-acquisition assignee landscape under IP analytics review.
Following the Sanofi acquisition, avapritinib is now part of the Sanofi portfolio. This post-acquisition context creates important IP ownership and commercial strategy considerations for the advanced SM indication, requiring analysis of both Blueprint Medicines and Sanofi as assignees across the European Patent Register and global patent databases.
To surface PATHFINDER-era publications and patent filings, applying a 2018–2024 date range filter is recommended. Cross-referencing external databases including ClinicalTrials.gov, PubMed, the USPTO full-text patent database, and the European Patent Register may hold relevant filings under Blueprint Medicines or Sanofi as assignees.
How to Obtain Data-Grounded Avapritinib Intelligence
The following steps are recommended to surface patent and literature records for avapritinib, KIT D816V inhibition, and the PATHFINDER trial landscape from verified, traceable sources.
Retry the Search with the Same Parameters
Database indexing delays or connectivity issues may have caused a null return. Re-querying with the same parameters — KIT D816V inhibition mechanisms, PATHFINDER clinical applications, Blueprint/Sanofi assignee landscape — may yield results on a subsequent attempt.
Broaden Query Terms to Proximal Literature
Alternative terms to capture proximal literature include "KIT D816V", "mastocytosis KIT inhibitor", "avapritinib Blueprint", or "ripretinib mast cell". These broaden the search scope to capture related filings and publications in the advanced systemic mastocytosis space.
Verified Databases for Avapritinib Patent & Clinical Intelligence
Search All These Sources Simultaneously in PatSnap Eureka
PatSnap Eureka unifies patent, clinical, and literature data for avapritinib in one searchable interface.
Avapritinib & Advanced Systemic Mastocytosis — Key Questions Answered
Avapritinib (Ayvakit) is a selective KIT D816V inhibitor developed by Blueprint Medicines. It represents a targeted therapeutic approach for advanced systemic mastocytosis (AdvSM), a rare and life-threatening mast cell neoplasm, by inhibiting the KIT D816V mutation that drives aberrant mast cell proliferation.
The PATHFINDER trial (ClinicalTrials.gov NCT03580655) and its expansion cohorts have been central to establishing avapritinib's clinical profile in advanced systemic mastocytosis. The trial spans multiple dimensions including KIT D816V inhibition mechanisms, systemic mastocytosis clinical applications, and assignee landscape analysis.
Avapritinib (Ayvakit) was developed by Blueprint Medicines and is now part of the Sanofi portfolio following acquisition. This post-acquisition context creates important IP ownership and commercial strategy considerations for the advanced systemic mastocytosis indication.
Relevant databases include ClinicalTrials.gov (NCT03580655 for PATHFINDER), PubMed, the USPTO full-text patent database, and the European Patent Register, which may hold relevant filings under Blueprint Medicines or Sanofi as assignees. PatSnap Eureka integrates these sources for unified intelligence.
Alternative search terms to capture proximal literature include KIT D816V, mastocytosis KIT inhibitor, avapritinib Blueprint, and ripretinib mast cell. Applying a 2018–2024 date range filter may surface relevant PATHFINDER-era publications and patent filings.
Generating analysis without grounded patent or literature records risks fabricating URLs, patent numbers, or assignee attributions, misrepresenting clinical trial status, regulatory decisions, or IP ownership, and producing analysis that cannot be traced to a verifiable source. Data-grounded analysis from verified records is essential for accurate intelligence.
Still have questions about avapritinib or advanced systemic mastocytosis patents? Let PatSnap Eureka answer them for you.
Ask Eureka About AvapritinibSearch the Full Avapritinib & KIT D816V Patent Landscape
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D. Search PATHFINDER trial data, Blueprint Medicines/Sanofi assignee records, and KIT D816V inhibition patents in one unified platform.
References
- ClinicalTrials.gov — PATHFINDER Trial NCT03580655: Avapritinib in Advanced Systemic Mastocytosis
- PubMed / MEDLINE — KIT D816V Inhibition and Systemic Mastocytosis Literature
- European Patent Office (EPO) — European Patent Register: Blueprint Medicines and Sanofi Assignee Filings
- United States Patent and Trademark Office (USPTO) — Full-Text Patent Database: KIT Inhibitor Filings
- PatSnap — Life Sciences Innovation Intelligence Platform
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Patent and literature search recommendations are derived from the PatSnap Eureka analytical framework for advanced systemic mastocytosis drug intelligence.
PatSnap Eureka searches patents and research to answer instantly.